Paulo Falabella, MD, PhD, Medical Director, Ophthalmology, Spark Therapeutics, talks about the significance of the approval of Luxturna (voretigene neparvovec-rzyl), which was the first gene therapy for an inherited disease approved in the United States.
Luxturna (Spark Therapeutics)
9 / 11 Series: OIS RETINA 2018
post as anonymous